Our previous studies also showed that positive Cbl-b expression was observed in 69.5% (107/154) receptor activator of nuclear factor κ-B (RANK) positive breast cancer samples (6), and 60.3% (73/121) patients with P-glycoprotein positive multiple drug resistance breast cancer (16). This evidence concerns the gene TNFRSF11A and breast cancer.